. 2022 Dec 22;29(Suppl):S261–S267. doi: 10.3350/cmh.2022.0393

Table 2.

Comparison of previous meta-analyses in which the effects of moderate alcohol consumption in NAFLD patients were assessed

Author	Year	Search	Number of included studies	Primary outcome	Participants (n)	Definition of moderate alcohol consumption	Pooled OR (95% CI)	Hetero geneity (I²)
Sookoian et al. [28]	2014	Unknown	8 studies	NAFLD prevalence	43,175	<40 g/day	0.684 (0.580–0.806)	NA
Cao et al. [26]	2016	Without restriction	13 cross-sectional studies, 2 cross-sectional following longitudinal studies, 1 cohort study	NAFLD prevalence	76,608	WHO definition	Light: 0.76 (0.72–0.80)	66%
Cao et al. [26]	2016	Without restriction		NAFLD prevalence	76,608	WHO definition	Moderate: 0.75 (0.70–0.80)	82.7%
Wijarnpreecha et al. [27]	2021	February 2019	6 cross-sectional studies	Prevalence of advanced liver fibrosis	8,936	<28 g/day for males	Modest drinkers vs. nondrinkers: 0.51 (0.35–0.75)	47%
Wijarnpreecha et al. [27]	2021	February 2019	6 cross-sectional studies	Prevalence of advanced liver fibrosis	8,936	<14 g/day for females	Modest drinkers vs. nondrinkers: 0.51 (0.35–0.75)	47%
Wongtrakul et al. [34]	2021	October 2020	14 cross-sectional or cohort studies	Prevalence of steatohepatitis	14,435	210 g/week for males	Steatohepatitis: 0.59 (0.45–0.78)	12%
Wongtrakul et al. [34]	2021	October 2020	14 cross-sectional or cohort studies	Prevalence of steatohepatitis	14,435	140 g/week for females	Advanced fibrosis: 0.59 (0.36–0.95)	75%

OR, odds ratio; CI, confidence interval; NAFLD, non-alcoholic fatty liver disease; WHO, World Health Organization.